{
     "PMID": "27780331",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170605",
     "LR": "20170605",
     "IS": "1555-2101 (Electronic) 0160-6689 (Linking)",
     "VI": "77",
     "IP": "12",
     "DP": "2016 Dec",
     "TI": "Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.",
     "PG": "e1631-e1638",
     "LID": "10.4088/JCP.15m10413 [doi]",
     "AB": "OBJECTIVE: Cortical thinning, previously identified during prodromal stages of Alzheimer's disease (AD), is a \"candidate\" biomarker implemented in AD clinical therapy trials. We investigated the effect of donepezil treatment on cortical thickness in mild cognitively impaired subjects with the amnestic syndrome of the hippocampal type, a prodromal at-risk group for progression to AD dementia. METHODS: Data were from a longitudinal analysis of a community-based multicenter suspected prodromal AD cohort diagnosed by the Free and Cued Selective Reminding Test (81 donepezil vs 92 placebo) enrolled in a double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day). The study started in November 2006 and concluded in August 2010. All subjects underwent 2 brain structural magnetic resonance imaging (MRI) scans, at baseline and at the end of the trial. Structural MRI images had been processed using the automated pipeline for longitudinal segmentation and surface reconstruction implemented in FreeSurfer. The primary outcome measure of this post hoc study was the annualized percentage change (APC) of cortical thickness. RESULTS: The donepezil group exhibited reduced APC cortical thinning compared to placebo in the rostral anterior cingulate (right: P = .048; left: P = .032), the orbitofrontal (right: P = .012; left: P < .048), and the right inferior frontal (P = .022) cortices and in the right insula (P = .010). These results were not statistically significant after Bonferroni correction likely due to insufficient power for cortical thickness measurements in the study group powered for the predefined hippocampus outcome. CONCLUSIONS: Our findings support the hypothesis that cortical thickness is a reliable candidate surrogate outcome in early predementia AD trials. In addition, donepezil treatment may have an impact on cortical structure/morphology in areas innervated by the medial and lateral cholinergic pathways. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00403520.",
     "FAU": [
          "Cavedo, Enrica",
          "Dubois, Bruno",
          "Colliot, Olivier",
          "Lista, Simone",
          "Croisile, Bernard",
          "Tisserand, Guy Louis",
          "Touchon, Jacques",
          "Bonafe, Alain",
          "Ousset, Pierre J",
          "Rouaud, Olivier",
          "Ricolfi, Frederic",
          "Vighetto, Alain",
          "Pasquier, Florence",
          "Galluzzi, Samantha",
          "Delmaire, Christine",
          "Ceccaldi, Mathieu",
          "Girard, Nadine",
          "Lehericy, Stephane",
          "Duveau, Francoise",
          "Chupin, Marie",
          "Sarazin, Marie",
          "Dormont, Didier",
          "Hampel, Harald"
     ],
     "AU": [
          "Cavedo E",
          "Dubois B",
          "Colliot O",
          "Lista S",
          "Croisile B",
          "Tisserand GL",
          "Touchon J",
          "Bonafe A",
          "Ousset PJ",
          "Rouaud O",
          "Ricolfi F",
          "Vighetto A",
          "Pasquier F",
          "Galluzzi S",
          "Delmaire C",
          "Ceccaldi M",
          "Girard N",
          "Lehericy S",
          "Duveau F",
          "Chupin M",
          "Sarazin M",
          "Dormont D",
          "Hampel H"
     ],
     "AD": "Universite Pierre et Marie Curie, 47 Blvd de l'Hopital, 75013 Paris, France. enrica.cavedo@gmail.com. Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Paris, France. INSERM U1127, Institut du Cerveau et de la Moelle Epiniere (ICM), Paris, France. Sorbonne Universites, Universite Pierre et Marie Curie-Paris 6, Paris, France . CATI multicenter neuroimaging platform (cati-neuroimaging.com), Paris, France . IRCCS Istituto Centro San Giovanni di Dio-Fatebenefratelli, Brescia, Italy. Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Paris, France. INSERM U1127, Institut du Cerveau et de la Moelle Epiniere (ICM), Paris, France. Sorbonne Universites, Universite Pierre et Marie Curie-Paris 6, Paris, France . Inserm, U1127, F-75013, Paris, France. CNRS, UMR 7225 ICM, 75013, Paris, France. Sorbonne Universites, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France. Institut du Cerveau et de la Moelle Epiniere, ICM, F-75013, Paris, France. Inria, Aramis project-team, Centre de Recherche Paris-Rocquencourt, France. Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Paris, France. INSERM U1127, Institut du Cerveau et de la Moelle Epiniere (ICM), Paris, France. Sorbonne Universites, Universite Pierre et Marie Curie-Paris 6, Paris, France . AXA Research Fund & UPMC, Paris, France. Department of Neuropsychology, Hopital Neurologique Pierre Wertheimer, Lyon, France. Hopital Neurologique Pierre Wertheimer, Lyon, France. CHRU, Gui de Chauliac, Montpellier, France. CHRU, Gui de Chauliac, Montpellier, France. Centre Memoire/Centre de Recherche Clinique-Gerontopole, Hopital Casselardit, Toulouse, France. Hopital General, Dijon, France. Hopital General, Dijon, France. Lyon 1 University, Hospices Civils de Lyon, Hopital neurologique, Service de Neurologie D, Lyon, France. Universite de Lille, Inserm U1171, CHU, Centre Memoire, 59000, Lille, France. IRCCS Istituto Centro San Giovanni di Dio-Fatebenefratelli, Brescia, Italy. Universite de Lille, Inserm U1171, Service de Neuroradiologie, Hopital Roger Salengro, Lille, France. Hopital de la Timone, Marseille, France. Hopital de la Timone, Marseille, France. INSERM U1127, Institut du Cerveau et de la Moelle Epiniere (ICM), Paris, France. Sorbonne Universites, Universite Pierre et Marie Curie-Paris 6, Paris, France . CENIR, Neuroimaging Unit, ICM, Hopital de la Salpetriere, Paris, France. Eisai SAS, La Defense 2 Cedex, France. Inserm, U1127, F-75013, Paris, France. CNRS, UMR 7225 ICM, 75013, Paris, France. Sorbonne Universites, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France. Institut du Cerveau et de la Moelle Epiniere, ICM, F-75013, Paris, France. Inria, Aramis project-team, Centre de Recherche Paris-Rocquencourt, France. Neurologie de la Memoire et du Langage, Universite Paris Descartes, Sorbonne Paris Cite, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France. Inserm, U1127, F-75013, Paris, France. CNRS, UMR 7225 ICM, 75013, Paris, France. Sorbonne Universites, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France. Institut du Cerveau et de la Moelle Epiniere, ICM, F-75013, Paris, France. Neuroradiology Department, Hopital de la Salpetriere, Paris, France. Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Paris, France. INSERM U1127, Institut du Cerveau et de la Moelle Epiniere (ICM), Paris, France. Sorbonne Universites, Universite Pierre et Marie Curie-Paris 6, Paris, France . AXA Research Fund & UPMC, Paris, France.",
     "CN": [
          "Hippocampus Study Group"
     ],
     "LA": [
          "eng"
     ],
     "SI": [
          "ClinicalTrials.gov/NCT00403520"
     ],
     "PT": [
          "Journal Article",
          "Multicenter Study",
          "Randomized Controlled Trial"
     ],
     "PL": "United States",
     "TA": "J Clin Psychiatry",
     "JT": "The Journal of clinical psychiatry",
     "JID": "7801243",
     "RN": [
          "0 (Indans)",
          "0 (Nootropic Agents)",
          "0 (Piperidines)",
          "8SSC91326P (donepezil)"
     ],
     "SB": "IM",
     "MH": [
          "Aged",
          "Aged, 80 and over",
          "Alzheimer Disease/diagnostic imaging/*drug therapy",
          "Amnesia/diagnostic imaging/*drug therapy",
          "Cerebral Cortex/*diagnostic imaging/drug effects",
          "Cognitive Dysfunction/diagnostic imaging/*drug therapy",
          "*Disease Progression",
          "Double-Blind Method",
          "Female",
          "Humans",
          "Indans/administration & dosage/*pharmacology",
          "Longitudinal Studies",
          "Magnetic Resonance Imaging",
          "Male",
          "Nootropic Agents/administration & dosage/*pharmacology",
          "*Outcome Assessment (Health Care)",
          "Piperidines/administration & dosage/*pharmacology",
          "*Prodromal Symptoms"
     ],
     "EDAT": "2016/10/26 06:00",
     "MHDA": "2017/06/06 06:00",
     "CRDT": [
          "2016/10/26 06:00"
     ],
     "PHST": [
          "2015/09/23 00:00 [received]",
          "2016/02/11 00:00 [accepted]",
          "2016/10/26 06:00 [pubmed]",
          "2017/06/06 06:00 [medline]",
          "2016/10/26 06:00 [entrez]"
     ],
     "AID": [
          "10.4088/JCP.15m10413 [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Clin Psychiatry. 2016 Dec;77(12):e1631-e1638. doi: 10.4088/JCP.15m10413.",
     "term": "hippocampus"
}